PROBIOTICS in antibiotics associated diarrhea
Diarrhoea is a common occurrence in association with antibiotic administration. Earlier studies and meta-analyses have suggested that probiotic administration reduces the incidence of antibiotic-associated diarrhoea (AAD).
Antibiotic-associated diarrhoea
(AAD) remains a prevalent condition in both in-patient and out-patient
settings. The prevalence of AAD is estimated at 5–39% and is associated with
increased costs and hospital length of stay.
AAD is a separate clinical entity from Clostridium difficile (C. difficile)-induced
diarrhoea and from C. difficile-associated pseudomembranous colitis. The
occurrence of AAD can be a limiting factor to adherence to antibiotic regimens
and to successful completion of treatment.
Probiotics are 'live microorganisms,
which, when consumed in adequate amounts, confer a health benefit on the host'.
Probiotic administration has been linked to modulation of gut mucosal immunity,
barrier function, metabolism and direct interaction with pathogenic bacteria.
These effects have been the rationale for the use of probiotics in a variety of
conditions affecting the gastrointestinal tract, including travellers'
diarrhoea, inflammatory bowel disease, irritable bowel syndrome, bacterial
overgrowth and C. difficile infection.
Probiotics have been used empirically for the
treatment and prevention of AAD.